<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1076</ReferenceId>
        <DateLastUpdated>2020-04-27-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10841792</PubmedId>
            <Abstract>Molecular features of ligand binding to MHC class II HLA-DR molecules have been elucidated through a combination of peptide structure-activity studies and structure-based drug design, resulting in analogues with nanomolar affinity in binding assays. Stabilization of lead compounds against cathepsin B cleavage by N-methylation of noncritical backbone NH groups or by dipeptide mimetic substitutions has generated analogues that compete effectively against protein antigens in cellular assays, resulting in inhibition of T-cell proliferation. Crystal structures of four ternary complexes of different peptide mimetics with the rheumatoid arthritis-linked MHC DRB10401 and the bacterial superantigen SEB have been obtained. Peptide-sugar hybrids have also been identified using a structure-based design approach in which the sugar residue replaces a dipeptide. These studies illustrate the complementary roles played by phage display library methods, peptide analogue SAR, peptide mimetics substitutions, and structure-based drug design in the discovery of inhibitors of antigen presentation by MHC class II HLA-DR molecules.</Abstract>
            <ArticleYear>2000</ArticleYear>
            <ArticlePages>2135-48</ArticlePages>
            <ArticleTitle>Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Bolin</LastName>
                    <ForeName>D R</ForeName>
                </Author>
                <Author>
                    <LastName>Swain</LastName>
                    <ForeName>A L</ForeName>
                </Author>
                <Author>
                    <LastName>Sarabu</LastName>
                    <ForeName>R</ForeName>
                </Author>
                <Author>
                    <LastName>Berthel</LastName>
                    <ForeName>S J</ForeName>
                </Author>
                <Author>
                    <LastName>Gillespie</LastName>
                    <ForeName>P</ForeName>
                </Author>
                <Author>
                    <LastName>Huby</LastName>
                    <ForeName>N J</ForeName>
                </Author>
                <Author>
                    <LastName>Makofske</LastName>
                    <ForeName>R</ForeName>
                </Author>
                <Author>
                    <LastName>Orzechowski</LastName>
                    <ForeName>L</ForeName>
                </Author>
                <Author>
                    <LastName>Perrotta</LastName>
                    <ForeName>A</ForeName>
                </Author>
                <Author>
                    <LastName>Toth</LastName>
                    <ForeName>K</ForeName>
                </Author>
                <Author>
                    <LastName>Cooper</LastName>
                    <ForeName>J P</ForeName>
                </Author>
                <Author>
                    <LastName>Jiang</LastName>
                    <ForeName>N</ForeName>
                </Author>
                <Author>
                    <LastName>Falcioni</LastName>
                    <ForeName>F</ForeName>
                </Author>
                <Author>
                    <LastName>Campbell</LastName>
                    <ForeName>R</ForeName>
                </Author>
                <Author>
                    <LastName>Cox</LastName>
                    <ForeName>D</ForeName>
                </Author>
                <Author>
                    <LastName>Gaizband</LastName>
                    <ForeName>D</ForeName>
                </Author>
                <Author>
                    <LastName>Belunis</LastName>
                    <ForeName>C J</ForeName>
                </Author>
                <Author>
                    <LastName>Vidovic</LastName>
                    <ForeName>D</ForeName>
                </Author>
                <Author>
                    <LastName>Ito</LastName>
                    <ForeName>K</ForeName>
                </Author>
                <Author>
                    <LastName>Crowther</LastName>
                    <ForeName>R</ForeName>
                </Author>
                <Author>
                    <LastName>Kammlott</LastName>
                    <ForeName>U</ForeName>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>X</ForeName>
                </Author>
                <Author>
                    <LastName>Palermo</LastName>
                    <ForeName>R</ForeName>
                </Author>
                <Author>
                    <LastName>Weber</LastName>
                    <ForeName>D</ForeName>
                </Author>
                <Author>
                    <LastName>Guenot</LastName>
                    <ForeName>J</ForeName>
                </Author>
                <Author>
                    <LastName>Nagy</LastName>
                    <ForeName>Z</ForeName>
                </Author>
                <Author>
                    <LastName>Olson</LastName>
                    <ForeName>G L</ForeName>
                </Author>
            </Authors>
            <Affiliations>Roche Research Center, Hoffmann-La Roche Inc., Nutley, New Jersey 07110, USA.</Affiliations>
            <ArticleChemicalList>Carbohydrates;Dipeptides;HLA-DR Antigens;Cathepsin B</ArticleChemicalList>
            <ArticleMeshHeadingsList>Antigen Presentation; Binding, Competitive; Carbohydrates(chemistry); Cathepsin B(metabolism); Cell Division(drug effects); Crystallography, X-Ray; Dipeptides(chemical synthesis; chemistry; pharmacology); HLA-DR Antigens(chemistry); Humans; Methylation; Models, Molecular; Molecular Mimicry; Peptide Biosynthesis; Protein Conformation; Structure-Activity Relationship; T-Lymphocytes(cytology; drug effects)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>43</Volume>
                <Issue>11</Issue>
                <Title>Journal of medicinal chemistry</Title>
                <Issn>0022-2623</Issn>
                <MedlineTa>J Med Chem</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>XRAMXSX</LinearSequence>
                        <ModifiedResidues>X1,X5,X7</ModifiedResidues>
                        <Modifications>Main chain modification</Modifications>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <EpitopeId>94970</EpitopeId>
                <ReferenceStartingPosition>1</ReferenceStartingPosition>
                <ReferenceEndingPosition>7</ReferenceEndingPosition>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <EpitopeComments>The epitope is a synthetic peptide based on the HA(306-318) epitope. Position 1 is occupied by acetyl-Cyclohexylalanine (Ac-(Cha)), Position 5 has Cys-Acm (CAcm) and Position 7 has Leucine-NH2 (L-NH2).</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <MhcBindingId>1514125</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>175</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>2.0</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>The crystal structure contains the MHC/epitope complex bound to the superantigen (SAG)  staphylococcal enterotoxin B (SEB). SAG PDB chain is D. The SAG was included in the complex as a vehicle to form crystals of MHC with novel compounds that diffract well. Clear electron density is observed for the MHC residues except for a loop consisting of residues B:105-112 and for the SAG molecule for a loop consisting of residues 99-108.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                        <ThreeDimensionalStructureOfComplex>
                            <ComplexPdbId>1D5M</ComplexPdbId>
                            <MhcChain1PdbChain>A</MhcChain1PdbChain>
                            <MhcChain2PdbChain>B</MhcChain2PdbChain>
                            <EpitopePdbChain>D</EpitopePdbChain>
                            <EpitopeResidues>D: (ALC)804, R805, A806, M807, (CY1)808, S809, (CLE)810;</EpitopeResidues>
                            <ViewerFlag>Y</ViewerFlag>
                            <Comments>[| P1: (ALC)804; P2: R805; P3: A806; P4: M807; P5: (CY1)808; P6: S809; P7: (CLE)810; |] The SAG molecule does not affect the MHC-Epitope interaction. The epitope is presented in the peptide binding groove in an extended conformation. Residues at positions P1, P2, P4, P6 and P7 are important for MHC-Epitope binding. Pocket 1 is deep and hydrophobic. The side chain of residue P5 projects out of the binding groove, where it is exposed and available to interact with a TCR.</Comments>
                            <CuratedContacts>
                                <EpitopeResidues>D: (ALC)804, R805, A806, M807, (CY1)808, S809, (CLE)810;</EpitopeResidues>
                                <EpitopeResiduesInteractingWithMhc>D: ;</EpitopeResiduesInteractingWithMhc>
                                <MhcResiduesInteractingWithEpitope>A: ; B: ;</MhcResiduesInteractingWithEpitope>
                            </CuratedContacts>
                            <CalculatedContacts>
                                <EpitopeResiduesInteractingWithMhc>D: (ALC)804, R805, A806, M807, (CY1)808, S809, (CLE)810</EpitopeResiduesInteractingWithMhc>
                                <MhcResiduesInteractingWithEpitope>A: Q9, E11, F24, I31, F32, W43, S53, F54, N62, V65, D66, N69; B: V11, H13, F26, D28, Y30, Y47, W61, L67, Q70, K71, A74, T77, Y78, H81, N82, V85, G86</MhcResiduesInteractingWithEpitope>
                                <ContactAreaForEpitope>929.6</ContactAreaForEpitope>
                                <ContactAreaForMhc>616.2</ContactAreaForMhc>
                            </CalculatedContacts>
                        </ThreeDimensionalStructureOfComplex>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>XRAXSX</LinearSequence>
                        <ModifiedResidues>X1,X4,X6</ModifiedResidues>
                        <Modifications>Main chain modification</Modifications>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <EpitopeId>94971</EpitopeId>
                <ReferenceStartingPosition>1</ReferenceStartingPosition>
                <ReferenceEndingPosition>6</ReferenceEndingPosition>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <EpitopeComments>The epitope is a synthetic peptidomimetic based on the HA(306-318) epitope. Position 1 is occupied by acetyl-Cyclohexylalanine (Ac-(Cha)), Position 4 has 9-amino-6,10-dioxoctahydropyridazino[1,2-a][1,2]diazepine-1-carboxylic acid (Odapdc) and Position 6 has Leucine-NH2 (L-NH2).</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <MhcBindingId>1514171</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>175</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>2.0</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>The crystal structure contains the MHC/epitope complex bound to the superantigen (SAG) staphylococcal enterotoxin B (SEB). SAG PDB chain is D. The SAG was included in the complex as a vehicle to form crystals of MHC with novel compounds that diffract well. Clear electron density is observed for the MHC residues except for a loop consisting of residues B:105-112 and for the SAG molecule for a loop consisting of residues 99-108.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                        <ThreeDimensionalStructureOfComplex>
                            <ComplexPdbId>1D5Z</ComplexPdbId>
                            <MhcChain1PdbChain>A</MhcChain1PdbChain>
                            <MhcChain2PdbChain>B</MhcChain2PdbChain>
                            <EpitopePdbChain>D</EpitopePdbChain>
                            <EpitopeResidues>D: (ALC)804, R805, A806, (ODA)807, S808, (CLE)809;</EpitopeResidues>
                            <ViewerFlag>Y</ViewerFlag>
                            <Comments>[| P1: (ALC)804; P2: R805; P3: A806; P4: (ODA)807; P5: S808; P6: (CLE)809; |] The SAG molecule does not affect the MHC-Epitope interaction. The epitope is presented in the peptide binding groove in an extended conformation. Residues at positions P1, P2, P4 and P6 are important for MHC-Epitope binding. Pocket 1 is deep and hydrophobic.</Comments>
                            <CuratedContacts>
                                <EpitopeResidues>D: (ALC)804, R805, A806, (ODA)807, S808, (CLE)809;</EpitopeResidues>
                                <EpitopeResiduesInteractingWithMhc>D: ;</EpitopeResiduesInteractingWithMhc>
                                <MhcResiduesInteractingWithEpitope>A: ; B: ;</MhcResiduesInteractingWithEpitope>
                            </CuratedContacts>
                            <CalculatedContacts>
                                <EpitopeResiduesInteractingWithMhc>D: (ALC)804, R805, A806, (ODA)807, S808, (CLE)809</EpitopeResiduesInteractingWithMhc>
                                <MhcResiduesInteractingWithEpitope>A: Q9, E11, F24, I31, F32, W43, S53, F54, N62, V65, D66, N69; B: V11, H13, Y30, Y47, W61, L67, K71, T77, Y78, H81, N82, V85, G86, F89</MhcResiduesInteractingWithEpitope>
                                <ContactAreaForEpitope>887.5</ContactAreaForEpitope>
                                <ContactAreaForMhc>561.1</ContactAreaForMhc>
                            </CalculatedContacts>
                        </ThreeDimensionalStructureOfComplex>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>XRXXX</LinearSequence>
                        <ModifiedResidues>X1,X3,X4,X5</ModifiedResidues>
                        <Modifications>Main chain modification</Modifications>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <EpitopeId>94973</EpitopeId>
                <ReferenceStartingPosition>1</ReferenceStartingPosition>
                <ReferenceEndingPosition>5</ReferenceEndingPosition>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <EpitopeComments>The epitope is a synthetic peptidomimetic based on the HA(306-318) epitope. Position 1 is occupied by acetyl-Cyclohexylalanine (Ac-(Cha)), Position 3 has N-Methylated Alanine (MeA), Position 4 has 5-amino-4-oxo-1,2,4,5,6,7-hexahydroazepino[3,2,1-hi]indole-2-carboxylic acid (Haic) and Position 5 has NHCH(CH2OH)2.</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <MhcBindingId>1514172</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>175</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>2.45</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>The crystal structure contains the MHC/epitope complex bound to the superantigen (SAG) staphylococcal enterotoxin B (SEB). SAG PDB chain is D. The SAG was included in the complex as a vehicle to form crystals of MHC with novel compounds that diffract well. Clear electron density is observed for the MHC residues except for a loop consisting of residues B:105-112 and for the SAG molecule for a loop consisting of residues 99-108.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                        <ThreeDimensionalStructureOfComplex>
                            <ComplexPdbId>1D5X</ComplexPdbId>
                            <MhcChain1PdbChain>A</MhcChain1PdbChain>
                            <MhcChain2PdbChain>B</MhcChain2PdbChain>
                            <EpitopePdbChain>D</EpitopePdbChain>
                            <EpitopeResidues>D: (ALC)804, R805, (MAA)806, (HAQ)807, (SEL)808;</EpitopeResidues>
                            <ViewerFlag>Y</ViewerFlag>
                            <Comments>[| P1: (ALC)804; P2: R805; P3: (MAA)806; P4: (HAQ)807; P5: (SEL)808; |] The SAG molecule does not affect the MHC-Epitope interaction. The epitope is presented in the peptide binding groove in an extended conformation. Residues at positions P1, P2 and P4 are important for MHC-Epitope binding. Pocket 1 is deep and hydrophobic.</Comments>
                            <CuratedContacts>
                                <EpitopeResidues>D: (ALC)804, R805, (MAA)806, (HAQ)807, (SEL)808;</EpitopeResidues>
                                <EpitopeResiduesInteractingWithMhc>D: ;</EpitopeResiduesInteractingWithMhc>
                                <MhcResiduesInteractingWithEpitope>A: ; B: ;</MhcResiduesInteractingWithEpitope>
                            </CuratedContacts>
                            <CalculatedContacts>
                                <EpitopeResiduesInteractingWithMhc>D: (ALC)804, R805, (MAA)806, (HAQ)807, (SEL)808</EpitopeResiduesInteractingWithMhc>
                                <MhcResiduesInteractingWithEpitope>A: Q9, E11, F24, I31, F32, S53, F54, N62, V65, D66; B: H13, D28, Y30, K71, T77, Y78, H81, N82, G86</MhcResiduesInteractingWithEpitope>
                                <ContactAreaForEpitope>755.7</ContactAreaForEpitope>
                                <ContactAreaForMhc>526.4</ContactAreaForMhc>
                            </CalculatedContacts>
                        </ThreeDimensionalStructureOfComplex>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>XRXMASX</LinearSequence>
                        <ModifiedResidues>X1,X3,X7</ModifiedResidues>
                        <Modifications>Main chain modification</Modifications>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <EpitopeId>94972</EpitopeId>
                <ReferenceStartingPosition>1</ReferenceStartingPosition>
                <ReferenceEndingPosition>7</ReferenceEndingPosition>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <EpitopeComments>The epitope is a synthetic peptidomimetic based on the HA(306-318) epitope. Position 1 is occupied by acetyl-Cyclohexylalanine (Ac-(Cha)), Position 3 has N-methylphenylglycine (MePhg) and Position 7 has tert-Leucine-NH2 (tL-NH2).</EpitopeComments>
                <Assays>
                    <MhcBinding>
                        <MhcBindingId>1514173</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>175</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>2.45</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>The crystal structure contains the MHC/epitope complex bound to the superantigen (SAG) staphylococcal enterotoxin B (SEB). SAG PDB chain is D. The SAG was included in the complex as a vehicle to form crystals of MHC with novel compounds that diffract well. Clear electron density is observed for the MHC residues except for a loop consisting of residues B:105-112 and for the SAG molecule for a loop consisting of residues 99-108.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>63</MhcAlleleId>
                        <ThreeDimensionalStructureOfComplex>
                            <ComplexPdbId>1D6E</ComplexPdbId>
                            <MhcChain1PdbChain>A</MhcChain1PdbChain>
                            <MhcChain2PdbChain>B</MhcChain2PdbChain>
                            <EpitopePdbChain>D</EpitopePdbChain>
                            <EpitopeResidues>D: (ALC)804, R805, (MPQ)806, M807, A808, S809, (BUG)810;</EpitopeResidues>
                            <ViewerFlag>Y</ViewerFlag>
                            <Comments>[| P1: (ALC)804; P2: R805; P3: (MPQ)806; P4: M807; P5: A808; P6: S809; P7: (BUG)810; |] The SAG molecule does not affect the MHC-Epitope interaction. The epitope is presented in the peptide binding groove in an extended conformation. Residues at positions P1, P2, P4, P6 and P7 are important for MHC-Epitope binding. Pocket 1 is deep and hydrophobic.</Comments>
                            <CuratedContacts>
                                <EpitopeResidues>D: (ALC)804, R805, (MPQ)806, M807, A808, S809, (BUG)810;</EpitopeResidues>
                                <EpitopeResiduesInteractingWithMhc>D: ;</EpitopeResiduesInteractingWithMhc>
                                <MhcResiduesInteractingWithEpitope>A: ; B: ;</MhcResiduesInteractingWithEpitope>
                            </CuratedContacts>
                            <CalculatedContacts>
                                <EpitopeResiduesInteractingWithMhc>D: (ALC)804, R805, (MPQ)806, M807, A808, S809, (BUG)810</EpitopeResiduesInteractingWithMhc>
                                <MhcResiduesInteractingWithEpitope>A: Q9, E11, F22, F24, F32, S53, F54, G58, A59, N62, V65, D66, N69; B: V11, H13, F26, D28, Y30, Y47, W61, L67, K71, A74, T77, Y78, H81, N82, V85</MhcResiduesInteractingWithEpitope>
                                <ContactAreaForEpitope>949.6</ContactAreaForEpitope>
                                <ContactAreaForMhc>619.5</ContactAreaForMhc>
                            </CalculatedContacts>
                        </ThreeDimensionalStructureOfComplex>
                    </MhcBinding>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

